Revolution Medicines, Inc.
Revolution Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on precision oncology. It develops small-molecule therapies designed to target RAS-addicted cancers, with its pipeline centered on RAS(ON) inhibitors and related combination approaches.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSmall-molecule therapies designed to inhibit the active, GTP-bound form of RAS in cancer cells.
Clinical and preclinical oncology programs built around genetic drivers and resistance biology.
Programs that test RAS-targeted agents with other therapies to improve response and durability.
Research collaboration arrangements that support discovery and biomarker work.
Customers
The company’s direct counterparties are primarily pharmaceutical collaborators, research partners, and contract manufacturers rather than end-market patients. If approved, its future customers would be oncologists, hospitals, cancer centers, and third-party payors that determine access and reimbursement for targeted cancer medicines.
Pharmaceutical and biotech partners that support discovery, preclinical work, or biomarker programs.
Cancer centers and physicians that enroll patients and generate clinical data for pipeline advancement.
Oncologists who would prescribe approved RAS-targeted therapies in relevant cancer indications.
Commercial insurers and government programs that determine coverage, pricing, and reimbursement.
Strategy
The company is building a portfolio of RAS(ON) inhibitors for RAS-addicted cancers and intends to retain meaningful development and commercialization rights. Its strategy combines internal drug discovery with collaborations, biomarker work, and combination-therapy development to improve the odds of clinical differentiation.
Clinical proof of concept is central to validating the platform and creating future product value.
Combination regimens and biomarker insights can improve response rates and patient selection.
A direct launch model requires medical, regulatory, manufacturing, and market access readiness.
Geography
Revolution Medicines is headquartered in the United States and expects its first commercial launch, if approved, to be in the U.S. before expanding to Europe and Asia. Its development and commercialization model is global in scope, but manufacturing is outsourced to third-party CDMOs and future market access will depend on country-specific reimbursement systems.
Risks
The business depends on successful clinical development of unproven RAS-targeted therapies, and failure in preclinical or clinical studies would materially impair the platform. As a clinical-stage biotech with no approved products, it also faces substantial financing, regulatory, manufacturing, and reimbursement risk before any commercial revenue can scale.
- Clinical development failureImpact: CriticalLikelihood: Medium
Pipeline value depends on demonstrating safety and efficacy in human trials.
Exposure: Lead RAS(ON) inhibitor programs
- Financing riskImpact: HighLikelihood: High
The company will need substantial capital before product sales can fund operations.
Exposure: Development and commercialization build-out
- Scientific uncertainty around direct RAS inhibitionImpact: HighLikelihood: Medium
The target has historically been difficult to drug, so the mechanism may not translate into durable approvals.
Exposure: RAS(ON) platform
- Manufacturing and supply dependenceImpact: MediumLikelihood: Medium
All manufacturing is outsourced to CDMOs, creating third-party execution and quality risk.
Exposure: Clinical and future commercial supply
- Reimbursement and pricing pressureImpact: MediumLikelihood: Low
Oncology drugs depend on coverage decisions and may face price controls or negotiation.
Exposure
Accounting
Judgemental itemsClinical and preclinical vendor invoices may lag service delivery, so estimates affect reported expenses and liabilities.
Impact: Can shift quarterly operating loss materially
Revenue from research agreements depends on performance obligations and contract termination terms.
Impact: Affects timing and amount of non-product revenue
The Royalty Purchase Agreement requires fair-value estimates of future royalty payments.
Impact: Can create significant non-cash balance-sheet and P&L volatility
Upfront payments to vendors are recognized over the period services are received.
Impact: Affects expense timing across reporting periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances)
Erasca, Inc.
ERAS · Pharmaceutical Preparations
BridgeBio Oncology Therapeutics, Inc.
BBOT · Pharmaceutical Preparations
Praxis Precision Medicines, Inc.
PRAX · Pharmaceutical Preparations
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026